Sudarshan Pharma Industries Ltd Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Cr

Consolidate Quarterly Results

Mar'26

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Net Sales

220.92

168.01

168.87

145.26

161.59

115.66

128.58

Other Operating Income

0.00

Total Operating income

220.92

168.01

168.87

145.26

161.59

115.66

128.58

Raw Material Cost

20.12

13.21

0.31

5.42

4.89

1.29

2.72

Purchase of Finished goods

192.61

148.81

171.18

139.53

160.89

111.46

122.83

(Increase) / Decrease In Stocks

-22.68

-14.22

-19.17

-15.73

-27.09

-11.27

-16.03

Employee Cost

2.10

1.97

1.78

1.58

1.31

1.28

1.12

Power Cost

0.00

Manufacturing Expenses

0.00

-0.01

0.00

-0.01

Selling and Distribution Expenses

0.00

Other Expenses

8.58

7.37

5.57

3.42

5.67

4.93

4.91

Total Expenditure (Excl Depreciation)

200.73

157.14

159.66

134.22

145.67

107.68

115.54

Operating Profit (PBDIT) excl Other Income

20.19

10.87

9.21

11.04

15.92

7.98

13.04

Other Income

4.13

1.52

1.86

1.21

0.84

0.51

0.32

Operating Profit (PBDIT)

24.32

12.39

11.07

12.25

16.76

8.49

13.36

Interest

7.53

6.28

5.94

5.96

4.40

4.00

3.70

Exceptional Items

0.00

-1.65

0.00

-1.17

Gross Profit (PBDT)

16.79

6.11

5.13

6.29

10.71

4.49

8.49

Depreciation

1.09

0.91

0.90

0.88

0.83

0.63

0.67

Profit Before Tax

15.70

5.20

4.23

5.41

9.89

3.85

7.83

Tax

4.31

1.05

0.36

1.45

2.48

0.97

1.95

Provisions and contingencies

0.00

Profit After Tax

11.39

4.15

3.87

3.96

7.41

2.88

5.88

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

11.39

4.15

3.87

3.96

7.41

2.88

5.88

Share in Profit of Associates

0.00

Minority Interest

0.67

-0.21

-0.31

-0.08

0.00

Other related items

0.00

Consolidated Net Profit

10.73

4.36

4.18

4.04

7.41

2.88

5.88

Equity Capital

24.07

Face Value

1.0

10.0

Reserves

0.00

Earnings per share (EPS)

0.45

0.18

0.17

0.31

0.12

0.24

Diluted Earnings per share

0.47

0.18

0.16

0.29

0.12

0.02

Operating Profit Margin (Excl OI)

9.14%

6.47%

5.45%

7.6%

9.85%

6.9%

10.14%

Gross Profit Margin

7.6%

3.64%

3.04%

4.33%

6.63%

3.88%

6.6%

PAT Margin

5.16%

2.47%

2.29%

2.73%

4.59%

2.49%

4.57%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Mar 2026 is 26.17% vs -5.17% in Dec 2025

Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 121.35% vs -2.05% in Dec 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Mar 2026 is 69.76% vs 12.06% in Dec 2025

Interest

QoQ Growth in quarter ended Mar 2026 is 16.51% vs 2.80% in Dec 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

Compare Quarterly Results Of Sudarshan Pharma With

Select Peers

Figures in Cr

Consolidate Quarterly Results

Change(INR)

Change(%)

Net Sales

220.92

317.61

-96.69

-30.44%

Other Operating Income

0.00

Total Operating income

220.92

317.61

-96.69

-30.44%

Raw Material Cost

20.12

203.89

-183.77

-90.13%

Purchase of Finished goods

192.61

2.18

190.43

8,735.32%

(Increase) / Decrease In Stocks

-22.68

3.60

-26.28

-730.00%

Employee Cost

2.10

17.57

-15.47

-88.05%

Power Cost

0.00

Manufacturing Expenses

0.00

0.01

-0.01

-100.00%

Selling and Distribution Expenses

0.00

Other Expenses

8.58

56.13

-47.55

-84.71%

Total Expenditure (Excl Depreciation)

200.73

283.38

-82.65

-29.17%

Operating Profit (PBDIT) excl Other Income

20.19

34.23

-14.04

-41.02%

Other Income

4.13

5.90

-1.77

-30.00%

Operating Profit (PBDIT)

24.32

40.13

-15.81

-39.40%

Interest

7.53

5.66

1.87

33.04%

Exceptional Items

0.00

Gross Profit (PBDT)

16.79

34.47

-17.68

-51.29%

Depreciation

1.09

5.79

-4.70

-81.17%

Profit Before Tax

15.70

28.67

-12.97

-45.24%

Tax

4.31

8.17

-3.86

-47.25%

Provisions and contingencies

0.00

Profit After Tax

11.39

20.51

-9.12

-44.47%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

11.39

20.51

-9.12

-44.47%

Share in Profit of Associates

0.00

Minority Interest

0.67

0.00

0.67

Other related items

0.00

Consolidated Net Profit

10.73

20.51

-9.78

-47.68%

Equity Capital

24.07

36.29

-12.22

-33.67%

Face Value

1.00

5.00

0.00

Reserves

0.00

Earnings per share (EPS)

0.45

2.83

-2.38

-84.10%

Diluted Earnings per share

0.47

2.73

-2.26

-82.78%

Operating Profit Margin (Excl OI)

9.14%

10.78%

0.00

-1.64%

Gross Profit Margin

7.60%

10.85%

0.00

-3.25%

PAT Margin

5.16%

6.46%

0.00

-1.30%

Public Share Holdings (%)

0.00%

0.00

0.00%

Pledged Promotor Holding (%)

0.00%

0.00

0.00%

Quarterly - Net Sales

Net Sales 199.81 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is 26.17% vs -5.17% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 23.67%

Quarterly - Standalone Net Profit

Standalone Net Profit 9.54 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is 121.35% vs -2.05% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 35.70%

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 18.30 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is 69.76% vs 12.06% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 20.24%

Quarterly - Interest

Interest 7.27 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is 16.51% vs 2.80% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 63.74%

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 9.16%

in Mar 2026

Figures in %

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

YoY Growth in quarter ended Mar 2026 has fallen from Mar 2025